Tick-borne Encephalitis virus NS1, Recombinant (TBEV)
Catalog No : USB-242957
778.18€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Tick-borne Encephalitis virus NS1, Recombinant (TBEV) | ||
|---|---|---|---|
| Catalog No | USB-242957 | ||
| Supplier’s Catalog No | 242957 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | |||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ≥90% pure by SDS-PAGE | ||
| Form | Supplied as a liquid in sterile dH2O, 0.09% sodium azide. | ||
| Reactivity life | 3 months | ||
| Note | For reserch purpose only | ||
| Purity | ≥90% pure by SDS-PAGE | ||
| Description | Tick-Borne Encephalitis Virus NS1 protein is produced entirely from human cell lines. The Tick-Borne Encephalitis Virus NS1 protein has been manufactured in response to a need for a highly purified, concentrated protein for use in serological based diagnostic products. The antigen is in its native folding state, and possesses all post-translational modifications. This advanced approach results in a product which delivers optimal antigenicity due to its human origin. The Tick-borne encephalitis virus (TBEV) is a Flavivirus which is transmitted to humans through a bite from an infected tick. Tick-borne encephalitis (TBE) is endemic in Europe and Asia with an average of 8,500 cases per year in Europe (wwwnc.cdc.gov/travel/yellowbook/2014/). TBE infected patients typically present with influenza-like symptoms and the disease is neuroinvasive often manifesting as meningitis, encephalitis or meningoencephalitis. Long-lasting or permanent neuropsychiatric sequelae are reported in 10 to 20% of patients. Tick-Borne Encephalitis Virus NS1 is presented in a hexameric state. Source: Encephalitis Virus NS1, Tick-Borne, strain Neudoerfl, from washed and lysed purified protozoa. Inactivation: Cells are lysed by sonication and freeze/thawing. Confirmed inactive by no visible growth in permissive media after 5 days compared to positive control. Storage and Stability: All NS1 products are shipped at ambient temperature. Extensive stability tests have shown no negative effects on antigen performance for 7 days of shipping including several freeze/thaw cycles. Aliquot to avoid repeated freezing and thawing and store at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Note: No test guarantees a product to be non-infectious. All materials should be handled as if potentially infectious. Generally accepted laboratory practices appropriate for infectious materials should be employed when handling this product. | ||
Product Details
© 2020 Imugex All Rights Reserved